{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T01:13:47Z","timestamp":1791422027321,"version":"4.3.3"},"reference-count":32,"publisher":"American Society for Microbiology","issue":"12","license":[{"start":{"date-parts":[[2018,11,26]],"date-time":"2018-11-26T00:00:00Z","timestamp":1543190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012399","name":"HHS | Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:p>\n                    We evaluated microbiological correlates for the successful treatment of\n                    <jats:named-content content-type=\"genus-species\">Neisseria gonorrhoeae<\/jats:named-content>\n                    isolates from a phase 2 study of gepotidacin, a novel triazaacenaphthylene antibacterial, for therapy of uncomplicated urogenital gonorrhea. Culture, susceptibility testing, genotypic characterization, and frequency of resistance (FoR) were performed for selected isolates.\n                  <\/jats:p>","DOI":"10.1128\/aac.01221-18","type":"journal-article","created":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T13:42:18Z","timestamp":1537537338000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":105,"title":["Microbiological Analysis from a Phase 2 Randomized Study in Adults Evaluating Single Oral Doses of Gepotidacin in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria gonorrhoeae"],"prefix":"10.1128","volume":"62","author":[{"given":"Nicole E.","family":"Scangarella-Oman","sequence":"first","affiliation":[{"name":"GlaxoSmithKline, Upper Providence, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Hossain","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Upper Providence, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula B.","family":"Dixon","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham, Birmingham, Alabama, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Ingraham","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Upper Providence, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Min","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Upper Providence, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney A.","family":"Tiffany","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Upper Providence, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline R.","family":"Perry","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Upper Providence, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aparna","family":"Raychaudhuri","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Upper Providence, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne F.","family":"Dumont","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Upper Providence, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianzhong","family":"Huang","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Upper Providence, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Edward W.","family":"Hook","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham, Birmingham, Alabama, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda A.","family":"Miller","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Upper Providence, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","unstructured":"Centers for Disease Control and Prevention. 2017. Reported STDs in the United States 2016. High burden of STDs threaten millions of Americans. Centers for Disease Control and Prevention Atlanta GA. www.cdc.gov\/nchhstp\/newsroom\/docs\/factsheets\/STD-Trends-508.pdf."},{"key":"e_1_3_3_3_2","unstructured":"Centers for Disease Control and Prevention. 2017. Sexually transmitted diseases surveillance 2016. Centers for Disease Control and Prevention Atlanta GA. www.cdc.gov\/std\/stats16\/CDC_2016_STDS_Report-for508WebSep21_2017_1644.pdf."},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00010-14"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002344"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002366"},{"key":"e_1_3_3_8_2","unstructured":"Centers for Disease Control and Prevention. 2013. Gonorrhea treatment guidelines: revised guidelines to preserve last effective treatment option. Centers for Disease Control and Prevention Atlanta GA. www.cdc.gov\/std\/treatment\/2010\/gonorrhea-treatment-guidelines-factsheet.pdf."},{"key":"e_1_3_3_9_2","unstructured":"World Health Organization. 2017. Global priority list of antibiotic resistant bacteria to guide research discovery and development of new antibiotics. World Health Organization Geneva Switzerland. www.who.int\/medicines\/publications\/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf?ua=1."},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30310-9"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-017-2931-x"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.EI10-0009-2015"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature09197"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02820-15"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02047-16"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy145"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1086\/510079"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-017-9518-0"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00182-11"},{"key":"e_1_3_3_20_2","volume-title":"Development of in vitro susceptibility testing criteria and quality control parameters","author":"Clinical and Laboratory Standards Institute","year":"2016","unstructured":"Clinical and Laboratory Standards Institute. 2016. Development of in vitro susceptibility testing criteria and quality control parameters, 4th ed. Document M23. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"4"},{"key":"e_1_3_3_21_2","volume-title":"Abstr 53rd Intersci Conf Antimicrob Agents and Chemother","author":"Hossain M","year":"2013","unstructured":"Hossain M, Tiffany CA, Day LA, Dumont EF. 2013. Population pharmacokinetic modeling of first-time-in-human data of GSK2140944, a novel antimicrobial compound. Abstr 53rd Intersci Conf Antimicrob Agents and Chemother, abstr F-1217."},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00115-16"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2011.00107"},{"key":"e_1_3_3_24_2","volume-title":"ASM Microbe","author":"Scangarella-Oman NE","year":"2016","unstructured":"Scangarella-Oman NE, Dixon P, Koeth LM, DiFranco-Fisher J, Miller LA. 2016. Analysis of agar dilution MIC testing methods and variables and in vitro activity of gepotidacin (GSK2140944) against Neisseria gonorrhoeae, poster Sunday-462. ASM Microbe, Boston, MA, 16 to 20 June 2016."},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-micro-090816-093530"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007435-200406000-00007"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02095-16"},{"key":"e_1_3_3_28_2","volume-title":"Abstr 54th Intersci Conf Antimicrob Agents and Chemother","author":"Hossain M","year":"2014","unstructured":"Hossain M, Tiffany CA, McDonald M, Dumont EF. 2014. Safety and pharmacokinetic of repeat escalating oral doses of GSK2140944, a novel bacterial topoisomerase inhibitor, abstr 2320. Abstr 54th Intersci Conf Antimicrob Agents and Chemother."},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky162"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/9781555817435"},{"key":"e_1_3_3_31_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard","author":"Clinical and Laboratory Standards Institute","year":"2015","unstructured":"Clinical and Laboratory Standards Institute. 2015. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 10th ed. Document M07-A10. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"10"},{"key":"e_1_3_3_32_2","volume-title":"Performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute","year":"2017","unstructured":"Clinical and Laboratory Standards Institute. 2017. Performance standards for antimicrobial susceptibility testing, 27th ed. Document M100-S27. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"27"},{"key":"e_1_3_3_33_2","unstructured":"Gonococcal Isolate Surveillance Program. 2016. Protocol. Centers for Disease Control and Prevention Atlanta GA. www.cdc.gov\/std\/gisp\/GISP-Protocol-May-2016.pdf."},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01104-08"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01221-18","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01221-18","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T16:17:23Z","timestamp":1645460243000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01221-18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["10.1128\/AAC.01221-18"],"URL":"https:\/\/doi.org\/10.1128\/aac.01221-18","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"2018-06-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-09-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01221-18"}}